AstraZeneca Expects Phase III Zactima Data For NSCLC In 2008
This article was originally published in The Pink Sheet Daily
Executive Summary
Company completes enrollment in ZEST trial evaluating the oral anti-cancer drug vandetanib compared to Tarceva.